OKYO - Okyo stock pops as eye drug package gets customs clearance to enter US
- London-based Okyo Pharma ( NASDAQ: OKYO ) it received customs clearance in the U.S. for its GMP packaged OK-101 drug, shipped from Europe, to be used in an upcoming phase 2 trial in patients with dry eye disease (DED).
- Okyo expects the first-patient-first visit in Q1 2023 and anticipates to release top-line data from the study in Q4 2023.
- "Initiation of the first-in-human Phase 2 trial for OK-101 to treat DED has been a central and critical goal for the company for the past 18 months," said Okyo CEO Gary Jacob.
- OKYO +2.50% to $2.46 premarket Feb. 28
For further details see:
Okyo stock pops as eye drug package gets customs clearance to enter US